Effectiveness of Biologic DMARDs in Rheumatoid Arthritis Compared

Syringe and Vials
Syringe and Vials
Researchers compared the real-world absolute and relative effectiveness in patients with RA of starting any of the available biologic DMARDs.

Outcomes observed in patients with rheumatoid arthritis (RA) suggest an equal or even superior effectiveness of non-tumor necrosis factor inhibitor (TNFi) biologics compared with TNFi therapy, according to results of a prospective study published in Rheumatology.

The investigators sought to compare the real-world absolute and relative effectiveness in patients with RA who were initiating treatment with any of the available biologic disease-modifying anti-rheumatic drugs (bDMARDs). The Swedish Rheumatology Register was used to identify patients with RA who initiated bDMARDs therapy (TNFi, rituximab, abatacept, or tocilizumab) between January 1, 2010, and December 31, 2016 as a first bDMARD (n=9333) or after a switch from TNFi as a first bDMARD (n=3941).

Therapeutic effectiveness was evaluated at 3 months and 1 year after initiation of treatment as the percentage of patients remaining on therapy and via the European League Against Rheumatism (EULAR) Good Response, Health Assessment Questionnaire (HAQ) improvement >0.2, 0 swollen and tender joints, and Clinical Disease Activity Index (CDAI) remission.

Study results showed that compared with patients receiving TNFi treatment a higher percentage of patients who started non-TNFi therapy  as their first bDMARD remained on their medication and achieved most response outcomes (1-year EULAR Good Response: TNFi, 24.9%; rituximab, 28.6%; abatacept, 31.9%; tocilizumab, 50.9%; HAQ improvement: TNFi, 25.4%; rituximab, 37.2%; abatacept, 33.7%; tocilizumab, 43.1%).

Following a switch from a first TNFi, rituximab and tocilizumab, but not abatacept, were associated with significantly better response measures than TNFi therapy (1-year EULAR Good Response: TNFi, 11.6%; rituximab, 24.8%; abatacept, 13.1%; tocilizumab, 34.1%; HAQ improvement: TNFi, 16.1%; rituximab, 33.2%; abatacept, 17.5%; tocilizumab, 29.4%). After adjustment for potential confounders, the differences remained significant.

Related Articles

The investigators concluded that treatment outcomes reported in patients with RA demonstrated the superior efficacy of non-TNFi bDMARDs, particularly tocilizumab and rituximab, compared with TNFi therapy. It should be noted that the safety and cost-effectiveness of individual bDMARDs were not analyzed in this study.

follow @RheumAdvisor


Frisell T, Dehlin M, Di Giuseppe D, Feltelius N, Turesson C, Askling J; ARTIS Study Group. Comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA: results from the nationwide Swedish register [published online January 21, 2019].  Rheumatology (Oxford). doi:10.1093/rheumatology/key433